Browsing Category
34427 posts
SEC encourages JTS bondholders to actively participate in the forthcoming bondholders’ meetings
The SEC advises JTS bondholders to gather information and actively participate in meetings on May 16 and 20, 2025, addressing defaults and restructuring for bonds JTS254A, JTS272A, and JTS282A. Decisions include waiving defaults, extending maturity, and restructuring repayments. Bondholders should consult the issuer for informed decisions.
OnCusp Therapeutics Announces Encouraging Initial Phase 1a Results from Ongoing First-in-Human Study Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors at the 2025 ASCO Annual Meeting
CUSP06 is a CDH6-directed ADC with a differentiated profile and potentially best-in-class…